The eCOA: Getting Better Together Initiative launched by the Critical Path Institute in 2019 aimed to identify and address
Ophthalmology clinical trials are essential for advancing treatments for various eye conditions such as cataracts, glaucoma, macular degeneration, and diabetic retinopathy. These trials face unique challenges due to the specificities of the indications and the patient population involved.
Patients with visual impairments may struggle to complete questionnaires accurately, leading to potential data inaccuracies and suboptimal patient experience, and patients may find it difficult to adhere to multiple data collection requirements and the requirements of lenghty studies.
Using eCOA solutions allows increased flexibility through appropriate device selection and through options such as font size adaptation, whilst following best practices and meeting industry standards.
As an active member of the eCOA Consortium, we contribute to develop best practices that incorporate strategies to best migrate and implement PROs. These best practices reflect the current consensus based on significant advances in technology capabilities, balancing the need for maintaining data integrity while optimizing usability.
While these best practices are not specific to the area of ophthalmology, their use is highly recommended to ensure fully informed and optimal ePRO implementation in ophthalmology clinical trials.
By implementing these best practices, we aim to positively impact the quality, practicality, and acceptability of the electronic capture of clinical trial endpoint data.
Last publications in collaboration with eCOA Consortium
The eCOA: Getting Better Together Initiative launched by the Critical Path Institute in 2019 aimed to identify and address
To address the need to embed flexibility in eCOA use, the “Support Flexible Approaches to PRO Data Collection” project
Kayentis announces that it has joined the C-Path’s ePRO Consortium, a nonprofit organization dedicated to advance the science of
Ophthalmic conditions and vision impairment currently affect 2.2 billion people globally: Data collection can be very challenging for patients
There is an extended use of Patient Reported Outcome (PRO) measures in clinical trials used to assess health-related quality
There is an extended use of Patient Reported Outcome (PRO) measures in clinical trials used to assess health-related quality
Ophthalmic conditions and vision impairment currently affect 2.2 billion people globally:
Kayentis offers tailored decentralized solutions with qualitative ePROs and extensive experience in ophthalmology to ensure the success of ophthalmology clinical trials by:
Kayentis Europe
19 bis, chemin du vieux Chêne
38240 Meylan
France
Phone: +33 (0)4 76 00 54 20
Kayentis US
186 South Street
Suite 600
Boston, Massachusetts 02111
USA
